Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients

被引:43
作者
Prandoni, Paolo [1 ]
Samama, Michel M. [2 ]
机构
[1] Univ Padua, Dept Med & Surg Sci, Thromboembolism Unit, I-35128 Padua, Italy
[2] Hotel Dieu Univ Hosp, Dept Haematol, Paris, France
关键词
venous thromboembolism; anticoagulation; thrombophilia; prevention; cancer;
D O I
10.1111/j.1365-2141.2008.07089.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Acute venous thromboembolism (VTE) is a serious and potentially fatal disorder, which often complicates the course of hospitalized medical patients. This is particularly true for carriers of malignant diseases. While the introduction of thromboprophylactic measures has probably affected the occurrence of postoperative VTE, there is an increasing awareness of the importance of medical conditions in determining thromboembolic events. Simple and clinically relevant risk assessment models are available to facilitate VTE risk assessment in hospitalized medical patients. Their validation in prospective studies is in progress. Randomized controlled clinical trials have consistently documented the efficacy of heparins and fondaparinux for prevention of VTE in hospitalized medical patients with a minimal haemorrhagic risk. Recognition of the incidence and clinical importance of thrombosis will probably encourage more widespread use of antithrombotic prophylaxis in medical patients and especially in some particular types of malignancies.
引用
收藏
页码:587 / 597
页数:11
相关论文
共 99 条
[1]
Epidemiology and risk factors of venous thromboembolism [J].
Ageno, Walter ;
Squizzato, Alessandro ;
Garcia, David ;
Imberti, Davide .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (07) :651-658
[2]
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness - Analysis of the MEDENOX study [J].
Alikhan, R ;
Cohen, AT ;
Combe, S ;
Samama, MM ;
Desjardins, L ;
Eldor, A ;
Janbon, C ;
Leizorovicz, A ;
Olsson, CG ;
Turpie, AGG .
ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) :963-968
[3]
A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer [J].
Altinbas, M ;
Coskun, HS ;
Er, O ;
Ozkan, M ;
Eser, B ;
Unal, A ;
Cetin, M ;
Soyuer, S .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (08) :1266-1271
[4]
Anderson AF, 2003, CIRCULATION S1, V107, P9, DOI [10.1161/01.CIR.0000078469.07362.E6, DOI 10.1161/01.CIR.0000078469.07362.E6]
[5]
THE PREVALENCE OF RISK-FACTORS FOR VENOUS THROMBOEMBOLISM AMONG HOSPITAL PATIENTS [J].
ANDERSON, FA ;
WHEELER, HB ;
GOLDBERG, RJ ;
HOSMER, DW ;
FORCIER, A .
ARCHIVES OF INTERNAL MEDICINE, 1992, 152 (08) :1660-1664
[6]
Arya R, 2007, BLOOD, V110, p214A
[7]
Venous thromboembolism and cancer [J].
Baron, JA ;
Gridley, G ;
Weiderpass, E ;
Nyrén, O ;
Linet, M .
LANCET, 1998, 351 (9109) :1077-1080
[8]
Heparin prophylaxis in bedridden patients [J].
Bergmann, JF ;
Caulin, C .
LANCET, 1996, 348 (9021) :205-206
[9]
Venous thromboembolism in the medically ill patient: a call to action [J].
Bergmann, JF ;
Kher, A .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (05) :555-561
[10]
Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels [J].
Berkowitz, DE ;
White, R ;
Li, DC ;
Minhas, KM ;
Cernetich, A ;
Kim, S ;
Burke, S ;
Shoukas, AA ;
Nyhan, D ;
Champion, HC ;
Hare, JM .
CIRCULATION, 2003, 108 (16) :2000-2006